U.S. markets closed
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • Dow 30

    28,725.51
    -500.10 (-1.71%)
     
  • Nasdaq

    10,575.62
    -161.89 (-1.51%)
     
  • Russell 2000

    1,664.72
    -10.21 (-0.61%)
     
  • Crude Oil

    79.74
    -1.49 (-1.83%)
     
  • Gold

    1,668.30
    -0.30 (-0.02%)
     
  • Silver

    19.01
    +0.30 (+1.62%)
     
  • EUR/USD

    0.9801
    -0.0018 (-0.19%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • GBP/USD

    1.1166
    +0.0043 (+0.38%)
     
  • USD/JPY

    144.7200
    +0.2770 (+0.19%)
     
  • BTC-USD

    19,149.83
    -182.80 (-0.95%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Novavax Scores Another Nod For Its COVID-19 Shot In Adolescents

·1 min read
  • The Medicines and Healthcare products Regulatory Agency in the U.K. has granted expanded conditional approval for Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine, Nuvaxovid (NVX-CoV2373), in adolescents aged 12 through 17.

  • The approval follows the FDA nod earlier this week.

  • "As we start to prepare for a potential fall surge, we are pleased to offer the first protein-based COVID-19 vaccine to adolescents aged 12 through 17 in the U.K.," said Stanley C. Erck, President, and CEO, of Novavax.

  • The expanded approval was based on data from the ongoing pediatric expansion of the Phase 3 PREVENT-19 trial of 2,247 adolescents.

  • Related: Novavax's Covid-19 Vaccine Cleared For Use In New Zealanders Aged 12-17.

  • Nuvaxovid achieved its primary endpoint in pediatric expansion and demonstrated 80% overall clinical efficacy when the Delta variant was predominant.

  • Also Read: Novavax Seeks FDA Emergency Use Nod For Its COVID-19 Vaccine Booster.

  • Preliminary safety data from the pediatric expansion showed the vaccine to be generally well-tolerated.

  • The U.K. approved the vaccine for adults as a two-dose regime in February.

  • Price Action: NVAX shares are down 4.48% at $35.58 on the last check Friday.

  • Photo by hakan german from Pixabay

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.